A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Public ClinicalTrials.gov record NCT05190471. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/Ib Study of BP1002 (a Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluates the safety and tolerability of escalating doses of BP1002 (Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is designed to assess the safety profile, identify DLTs, biologically effective doses, PK, PD and potential anti-leukemic effects of BP1002 as single agent (dose escalation phase) followed by assessing BP1002 in combination with decitabine (dose expansion phase).
Study identification
- NCT ID
- NCT05190471
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 48 participants
Conditions and interventions
Interventions
- BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide Drug
- Decitabine (in combination with BP1002) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 15, 2022
- Primary completion
- Feb 28, 2027
- Completion
- Aug 31, 2027
- Last update posted
- Mar 9, 2025
2022 – 2027
United States locations
- U.S. sites
- 4
- U.S. states
- 3
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Scripps Green Hospital | La Jolla | California | 92037 | Recruiting |
| UCLA Medical Center | Los Angeles | California | 90024 | Recruiting |
| Weill Cornell Medical College - NewYork-Presbyterian Hospital | New York | New York | 10021 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Acute Myeloid Leukemia Refractory trials
Other public records listing Acute Myeloid Leukemia Refractory. Sorted by last update posted; newest first. Not a recommendation.
- NCT07011004: A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia Recruiting
- NCT04716452: Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia Recruiting
- NCT06017258: A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia Recruiting
- NCT05317403: Venetoclax to Augment Epigenetic Modification and Chemotherapy Recruiting
- NCT05105152: PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML Recruiting
- NCT06680752: Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05190471, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 9, 2025 · Synced Aug 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05190471 live on ClinicalTrials.gov.